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Summary Patients with epilepsy, treated with antiepileptic drugs (AEDs) are at
increased risk of fractures. Although several commonly used AEDs reduce bonemass in
patients, the mechanisms are only scarcely known. In this review, we focus on the
usefulness of animal models to explore the skeletal effects of AEDs. Moreover, we
report our findings from a recent study comparing the effect of levetiracetam (LEV),
phenytoin (PHT) and valproate (VPA) on various aspects of bone health in actively
growing female rats. Our data indicate that these AEDs act differently on bone mass,
structure and metabolism. A novel finding is that LEV reduces bone strength and bone
formation without altering bone mass. Based on these results we propose that
epidemiological fracture studies of patients treated with LEV are needed, and that
these patients should be evaluated regularly to identify possible bone-related side
effects.
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An association between antiepileptic drug (AED)
therapy, lowered bone mineral density (BMD) and
fracture risk has been repeatedly reported over the
last 40 years (reviewed in1). The most common
fracture sites are spine and hip but the relative risk
of any fracture is increased.1,2 AED-related bone
disease affects both genders, although female epi-
lepsy patients have the highest risk of fracture
because of the added burden of postmenopausal
osteoporosis.Animal models
The mechanisms responsible for AED-related bone
fragility are multiple and still inadequately under-
stood. Animal studies are helpful in this respect,
because they allow us to eliminate all the possible
variation caused by life style, genetics, individual
disease characteristics and compliance. However,
extrapolation of results from animal model studies
to the human clinical situation require careful con-
sideration of the relevance of the animal model,
including the age of the animals, duration of treat-
ment and the concentrations of drugs used in the
experiments.
The laboratory rat has been widely used to
study the effects of drugs on bone health,3 and
Refs. in.4,5 However, relatively few animal studies
have investigated the effects of common AEDs like
valproate (VPA) and phenytoin (PHT), representing
enzyme-inducing and non-inducing drugs, respec-
tively. Moreover, most previous studies were
conducted in male animals,6—8 and whether
AEDs cause gender-specific effects on bones is
unknown.
PHT causes bone loss due to elevated bone
resorption in intact animals,7,8 but has also been
shown to have direct effects on osteoblast prolif-
eration and differentiation in cell culture experi-
ments.9—12 The reported effects of VPA on human
bone turnover differ widely (see 2 for review), and
also effects of VPA on cultured bone cells vary from
inhibition13 to enhancement.14 The newer AEDs
have been little studied.15 With respect to levetir-
acetam (LEV), no adverse skeletal effects werereported by the manufacturer before registration
of Keppra1 (UCB Pharma).Evaluation of bone quality
Although the diagnosis of osteoporosis or AED-
induced osteopenia currently is based on measure-
ment of bone mineral density (BMD), additional
factors are known to increase fracture risk, inde-
pendent of BMD.16,17 Among these, bone turnover
reflects changes in the rate of bone remodelling,
and is assessed by measurements of alterations in
biochemical markers of bone formation and resorp-
tion. Bone strength also depends upon structural
and material properties (e.g. micro-architecture,
geometry and matrix composition),18 which are
assessed by histomorphological methods. Whereas
in human studies fracture risk is the primary clinical
endpoint, methods for in vivo bone quality evalua-
tion are not available in a clinical setting. Instead,
surrogate measures like biomechanical strength
(three-point bending) can be applied in animal
models.Adolescent female rats treated with
AEDs
In a recent study we investigated various aspects
of bone health in growing female rats treated with
clinically relevant doses of LEV, PHTand VPA.19 We
used female Wistar rats at 80 days of age, com-
parable to human adolescents.4,5 To ascertain that
the dose of the respective AEDs reproduced serum
concentrations corresponding to the therapeutic
ranges for humans, serum concentrations were
measured and the doses adjusted accordingly
(Table 1).19 The chosen drug dose duration (90
days, representing about 20 oestrous cycles in
rats, corresponding to ca. 2 years of menstrual
cycles in women) was considered sufficient to
mimic long-term AED treatment in humans, well
above the minimum duration for women taking
part in studies of AEDs and endocrine effects.20 As
shown in Table 1, weight gain was normal with no
significant differences between the treatment
groups.
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Table 1 Weight and AED serum concentrations after 90 days of drug administration
Groups (1) Low-dose
LEV (n = 14)
(2) High-dose
LEV (n = 19)
(3) PHT
(n = 15)
(4) VPA
(n = 17)
(5) Control
(n = 23)
Administered dose (mg/kg) 50 150 50 300 —
Weight (g; mean  S.D.) 249  10 253  26 242  8 252  17 252  15
Serum drug concentration
(mmol/l; mean  S.D.)
122  41 277  65 37  14 431  248 —
The dose (administered twice daily) for each drug is shown, together with weight at the end of the study and AED serum
concentrations (measured 4 h after last dose administration). Drug doses fed to rats were higher than those commonly used in
humans, whereas the actual serum drug concentrations were not. Although serum levels of LEV in the high-dose group exceeded the
commonly used therapeutic range, such levels can be observed in patients without side-effects. Reproduced with permission from.19.Measurements of bone mass by DXA (Dual energy
X-ray Absorptiometry) demonstrated that BMC/BMD
tended to be reduced by VPA and PHT, whereas LEV
did not induce changes in these parameters
(Figure 1A). Biomechanical strength (assessed by
three-point cantilever bending) of the femoral neck
was significantly reduced by low-dose LEV only
(Figure 1B). By comparison, no significant effects
were observed in the strength of the femoral shaft
(diaphysis) for any of the AEDs, although PHT, VPA
and high-dose LEV tended to reduce strengthFigure 1 Bone quality parameters evaluated in AED-treat
#p < 0.05 when all groups were compared using Kruskal—Willi
significant. (B) Biomechanical strength (ultimate momentum)
(MANOVA/Bonferroni post hoc test). (C) Ultimate momentum
bone formation marker osteocalcin. Comparison of all groups w
group 5 (Dunnett t-test), #p < 0.05 compared to group 1 (Bonf
LEV; (3) PHT; (4) VPA; (5) Control. The figure is modified from(Figure 1C). Bone turnover was assessed by monitor-
ing changes in serum levels of osteocalcin (bone
formation marker) and RatLaps (bone resorption
marker; collagen degradation products). The results
showed that VPA increased bone turnover, whereas
low-dose LEV reduced bone formation (Figure 1D).
Histomorphometric analysis of the femoral neck
indicated increased content of cartilage remnants
in the metaphysis from LEV-treated versus control
rats, whereas the relative trabecular bone volume
and bone marrow space tended to be decreased ined rats. (A) Bone mineral content (BMC) of total femur.
s test. Post hoc tests for comparing single groups were not
of femoral collum. #p < 0.05 compared to groups 2 and 4
of the femoral diaphysis. (D) Serum concentration of the
ith Kruskal—Wallis test: p = 0.007. *p < 0.05 compared to
erroni). Treatment groups: (1) low-dose LEV; (2) high-dose
.19
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Figure 2 Morphological parameters of femurs from rats
treated with low-dose LEV compared to vehicle-treated
controls. Results represent the mean  S.D. of 6 animals
in each group. Reproduced with permission from.19the LEV-treated bones (Figure 2). These structural
differences in the properties of bone and cartilage
are likely of importance for the observed change in
biomechanical strength induced by low-dose LEV
(Figure 1B).Effect of VPA and PHT on adolescent
female rats
Our findings that VPA and PHT treatment resulted in
reduced bone mass at various skeletal sites, paral-
leled by increased bone turnover (for VPA), and a
slightly reduced mechanical strength in the femoral
shaft of these bones,19 are consistent with the
increased fracture risk associated with these drugs
in humans.1,2,16 Furthermore, they are in concor-
dance with experimental data from male rats trea-
ted with AEDs,6,8 and indicate different mechanisms
of action for VPA and PHT in bone.LEV has a biphasic effect on bone
In this first report on effects of clinically relevant
concentrations of LEV on bone,19 our data demon-
strate that low-dose LEV causes selective reduction
of biomechanical strength of the femoral neck with-
out affecting bone mass. Moreover, bone formation
is significantly reduced in LEV-treated rats as
assessed by decreased serum osteocalcin levels rela-
tive to controls. Although previous studies did not
report any effect of LEV on bone mass,15,21 these
results suggest that skeletal health may still be
compromised by this drug. Since high-dose LEV does
not impact these bone parameters, our data sug-gests a dose-dependent, biphasic effect of LEV in
bone. Similarly, the more profound effect of low-
dose than high-dose LEV on serum estradiol levels in
the same rats 22 support this notion.
The femoral neck represents metabolically active
trabecular bone, and is also the site where epilepsy
patients are at increased risk for fractures.1,2 One
possible mechanism by which LEV might cause
impaired strength of the femoral neck is by altera-
tion of bone microstructure/architecture. Consis-
tent with this, histomorphometric data indicated
increased content of cartilage remnants in the
metaphysis of LEV-treated animals versus con-
trols.19 Bone trabeculae containing relatively more
cartilage and therefore relatively less mineralized
bone, would likely show impaired bone strength of
the femoral neck. Prepubertal rather than fertile
animals are susceptible to the effects of LEV on
endocrine function.22,23 Taken together, these ani-
mal studies suggest that young individuals, in parti-
cular, should be carefully monitored in future
clinical studies for potential impairment of bone
growth due to disturbances in the microstructure
of the epiphyseal growth plate.
Thus, the effect of low-dose LEVon bone strength
in skeletally immature rats may have consequences
for longitudinal skeletal growth and fracture risk.
Because of the differences in bone growth and
metabolism between rats and humans, human
observations in epidemiologic studies including frac-
ture data are needed to clarify this issue. LEV pre-
scription for children and adolescents with epilepsy
is growing, therefore these patients should be mon-
itored for signs of AED-related skeletal distur-
bances. Recommendations for monitoring of bone
health in AED-treated patients focus on DXA mea-
surements to detect reduced bone mass,16,24 but
official guidelines for prevention of bone loss in
epilepsy patients do not exist. The knowledge that
LEV-treated rats display compromised bone
strength, reflecting alterations in bone structure/
material properties and bone turnover rate, despite
normal BMD, suggests increased fracture risk for
long-term users of this drug.2,25 Thus, controlled
clinical studies are necessary to assess the effect of
LEV on bone development and growth in children
and adolescents, eventually resulting in new ther-
apeutic guidelines.Conclusion
Accumulating evidence that AED treatment in epi-
lepsy patients not only reduces bone mass, but also
affects bone quality and strength,2 emphasize the
need for experimental animal models to assess the
Skeletal effects of AEDs in rats 191safety and mechanisms of action for new AEDs in the
skeleton. Monitoring of bone quality is problematic
in humans; animal models provide an additional
system in which the properties of bone and the
influence of drugs can be explored, isolated from
disease, lifestyle and other confounding factors.
Although side effects of the newer AEDs may seem
subtle, they might be important in an epidemiologic
perspective. LEV, PHT and VPA have differential
effects on bone mass, structure and metabolism.19
Notably, our data indicate that LEV does not affect
bone mass, but has a biphasic effect on bone for-
mation indices and biomechanical bone strength of
the femoral neck (mainly trabecular bone). Finally,
the lack of treatment guidelines for patients on AED
therapy in order to reduce fracture risk is discussed.Conflict of interest statement
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